

**Oramed Pharmaceuticals Inc. (ORMP – \$8.24\*)**
**Company Update**

Jerusalem, Israel  
July 7, 2016

**Outperform**  
Price Target: \$20.00

**STOCK DATA**

52-Week Range	\$10.74 – \$4.15
3-Month ADTV	163,300
Dividend Yield	NA
Market Cap (mil)	\$108.2
Shares Outstanding (mil)	13.1
Beta	0.02
Float (%)	78.7
Fiscal Year-End	August

**EARNINGS DATA**

EPS	2015A	2016E	2017E
1Q	(\$0.19)	(\$0.21)A	—
2Q	(\$0.15)	(\$0.15)A	—
3Q	(\$0.15)	(\$0.16)A	—
Prior 3Q	--	(\$0.20)	--
4Q	(\$0.18)	(\$0.23)	—
Prior 4Q	--	(\$0.22)	--
FY	(\$0.67)	(\$0.76)	(\$0.79)
Prior FY	--	(\$0.78)	(\$0.81)

**BALANCE SHEET DATA**

	3Q16
Cash & Equivalents	\$35.9
Current Assets	\$26.0
Total Assets	\$38.4
Total Liabilities	\$5.7
Total Stockholder Equity	\$32.7
Total Debt	\$0.0

*\$ in millions.*

## F3Q16 Earnings: HTIT Intent to Deliver \$6.5M Milestone Payment Following Positive Phase IIb Data

### Summary and Recommendation

On July 6, Oramed Pharmaceuticals released its F3Q16 performance and provided a corporate update in a 10-Q filing. As a reminder, Oramed is developing two clinical candidates: ORMD-0801, an oral insulin analog for the treatment of type 1 and type 2 diabetes (T1D and T2D), and ORMD-0901, an oral GLP-1 analog for the treatment of T2D. Although the company does not host a quarterly earnings call, we saw several positive developments made during the quarter and provide four key takeaways: (1) we remain focused on full data from the Phase IIb study with ORMD-0801 in patients with Type II diabetes (T2D), which read out positive top-line data in May; (2) we believe these full data could support a partnership for late-stage development and commercialization; (3) Hefei Tianhui Incubator of Technologies Co. (HTIT), Oramed's Chinese partner for ORMD-0801, announced its intent to make a \$6.5 million milestone payment in 3Q16 per conditions of the Chinese license agreement; and (4) we expect data from a non-FDA approved study with ORMD-0901 in T2D patients in 3Q16. Overall, we believe Oramed has made significant progress during the quarter and remain focused on the full data set from the Phase IIb study with ORMD-0801.




### Key Points

- **Focus remains on full Phase IIb data with ORMD-0801.** We remind investors that full data from the study could help clarify the existence of a dose effect and resolve concerns over a cited manufacturing fault with the 16 mg capsule. In the Phase IIb study, ORMD-0801 was dosed with 2 x 8 mg capsules and 3 x 8 mg capsules in order to avoid a potential manufacturing fault of the 16 mg capsules. We believe these data will help clarify a dose-related response, which could provide an additional catalyst for the stock. In conjunction, Oramed is conducting an ongoing glucose clamp study in order to quantify insulin absorption and measure insulin sensitivity in T2D patients.
- **HTIT declares intention to make \$6.5 million milestone payment.** In June, HTIT provided its intent to make a \$6.5 million payment following the positive Phase IIb top-line readout. Oramed remains eligible to receive approximately \$10 million to \$15 million in milestone payments, including the \$6.5 million payment expected in 3Q16. In addition to the partnership with HTIT, we see a potential partnership on the horizon, supported by the full Phase IIb study with ORMD-0801.
- **Expecting ORMD-0901 data from non-FDA-approved study in 3Q16.** Oramed announced completion of final visits for the study in T2D patients in 2Q16 and expects data from the study during this quarter. The company anticipates initiating IND-enabling studies in the first quarter of 2017, followed by an U.S. IND filing and Phase II multi-center trial in the U.S.
- **F3Q16 earnings details.** Oramed reported F3Q16 earnings per share of (\$0.16), compared with (\$0.15) in F2Q16. R&D spending increased to \$1.7 million in F3Q16 from \$1.3 million in F2Q16. G&A spend decreased to \$0.6 million from \$0.7 million in F2Q16. As of May 31, 2016, the company reported a cash and equivalents balance of \$35.9 million, which provides sufficient cash runway through 2017, according to our model.

Christopher S. James, M.D.  
646.885.5470 . cjames@fbr.com

Justin A. Kim  
646.885.5426 . justinkim@fbr.com

## The Debate™

Debatable Point	Our Thoughts	Time Frame	Impact
Will ORMD-0801 show positive safety and efficacy in the current Phase IIb study?	Oramed announced positive top-line results in May from its Phase IIb study. We believe the data highlight activity of oral insulin analog ORMD-0801. Pooled data from the Phase IIb study demonstrated a statistically significant decrease of 6.47% ( $p = 0.0268$ ) in the primary endpoint of mean night-time fasting glucose at four weeks from baseline, as compared to placebo. We are interested to see additional data, including dose-related efficacy at 16 mg and 24 mg dose levels. As a reminder, the Phase IIa study showed evidence of a manufacturing fault associated with the 16 mg capsule (24 mg dose), which makes the existence of a dose-related effect less clear. That being said, we think there is a significant market opportunity for oral insulin if the full Phase IIb outcome is positive, and we view the risk/reward profile as favorable.	3 Months	
Will Oramed successfully partner ORMD-0801 to support late-stage clinical trials, approval, and commercialization?	If ORMD-0801 is shown to be both safe and effective, Oramed plans to ultimately seek a strategic partner or partners with extensive drug development experience and marketing capabilities. Given the size and scope (approximately 3,000 patients over 24 weeks) of a Phase III program in T1D and T2D, we would expect Oramed to attempt to partner ORMD-0801 after the Phase II studies are complete. The strategic partner(s) would be responsible for global clinical trials, post-marketing studies, and label expansion, which are outside of Oramed's core developmental capabilities. We expect to see a partnership or partnerships following Phase IIb data, which are expected to read out in the 3Q16.	6 to 18 Months	
Will Oramed's oral GLP-1 candidate (ORMD-0901) prove to be safe and effective in T2D patients?	ORMD-0901 is an oral exenatide GLP-1 analog-based preparation designed with Oramed's oral formulation technology. Oramed completed non-FDA approved clinical trials of ORMD-0901 in healthy volunteers at a medical center in Jerusalem. The first-in-human study demonstrated retained biological activity on insulin excursions after oral administration of ORMD-0901 followed by an oral glucose load. While these data are encouraging and provide a rationale for advanced development, only six subjects were analyzed for safety, and only four subjects were considered for the efficacy evaluations due to adverse events reported upon glucose load.	2 Years+	

## Investment Thesis

Given its focus on developing orally administered peptides that are currently available only as injectables, we view Oramed as owning platform technology with a strong patent estate. We believe the data for both ORMD-0801 and ORMD-0901 are compelling and remain buyers of the stock, especially at current levels.

## Valuation

Our \$20 price target is based on probability-weighted DCF and sum-of-the-parts (SOTP) analyses of the commercial opportunities available to the company.

## Catalysts/Milestones

- 3Q16: complete Phase Ib ex-U.S. study with ORMD-0901 in T2D.
- 2017: initiate Phase II multi-center study with ORMD-0901 oral GLP-1 analog.

## Valuation Methodology

Our \$20 price target is based on probability-weighted DCF and sum-of-the-parts (SOTP) analyses of the commercial opportunities available to the company. Our model incorporates a 13.5% discount rate, which is in line with development-stage companies. We ascribe a 30% probability of success (PoS) to ORMD-0801 in T1D and T2D. Our SOTP analysis shows that 76% of the total value of ORMP can be ascribed to ORMD-0801 T2D, given its large market size relative to T1D, and ORMD-0901 GLP-1 for T2D patients. We ascribe a 10% PoS to ORMD-0901, which completed a Phase I study in healthy volunteers.

### ORMP Sum-of-the-Parts Analysis (\$ in Millions)

	EV	PoS	=	EV		Per Diluted Share	
ORMD-0801 - T2D	670.3	* 30.0%	=	201.1	76%	15.33	76%
ORMD-0801 - T1D	119.2	* 30.0%	=	35.8	14%	2.73	14%
ORMD-0901 GLP-1 - T2D	264.2	* 10.0%	=	26.4	10%	2.01	10%
Total Firm Value	1,053.7	* 25.0%	=	263.3	100%	20.07	100%
<b>Total Equity Value</b>				<b>263.3</b>	100%	<b>20.07</b>	100%
Fully Diluted Shares						13.1	

Source: FBR Research

### ORMP DCF Analysis (\$ in Millions)

Present Value of FCF	1,053.7
Blended PoS	0.25
Present Value of Equity	263.3
Diluted Shares Outstanding	13.1

Equity Value per Share

**\$ 20.07**

#### Terminal Value Summary

Perpetual Growth Rate	2.0%
Terminal Free Cash Flow	404.6
Terminal Value	3,524.9
Present Value of FCF	1,053.7
Present Value of TV	589.1
<b>Terminal Value % of EV</b>	<b>55.9%</b>

Source: FBR Research

## Risks

**Clinical risks.** The development of clinical drug candidates is inherently risky and may never lead to marketable products. Oramed's lead drug candidate, ORMD-0801, is at an early stage of clinical development and depends on third-party suppliers for raw materials. As the company does not control these parties, it is not able to guarantee that the clinical operations will be performed in a timely and adequate manner.

**Competitive risks.** Several companies are developing candidates or marketing products for the same treatment indications for which Oramed is developing product candidates. These candidates or products may negatively affect future pricing power or market opportunities for Oramed's developmental candidates.

**Financial risks.** Oramed is currently developing several clinical candidates and may need additional funds in the future to continue research and development programs and for the commercialization of its products.

**Liquidity risk.** The company has a relatively small float with a market capitalization of approximately \$100 million on common shares outstanding. Investors could potentially be at risk of finding a liquid market to buy or sell shares.

**Regulatory risks.** There is a risk that the company will be unable to receive regulatory approvals or experience delays in receiving approval. Additionally, the company must obtain several foreign regulatory approvals to be able to sell products internationally.

**Manufacturing risks.** Oramed may be unable to manufacture or contract with third parties for the manufacture of insulin-based applications and/or other orally digestible drugs.

## Company Profile

Oramed Pharmaceuticals Inc. develops a proprietary platform technology focused on creating orally administered oral polypeptides. The company has two oral candidates in development in the diabetes space: ORMD-0801, an insulin analog for type 1 diabetes (T1D) and type 2 diabetes (T2D); and ORMD-0901, an oral GLP-1 analog for type 2 diabetes (T2D). ORMD-0801 recently completed a Phase IIb study in T2D patients, which read out positive top-line data in May 2016. In 1Q17, Oramed plans to initiate IND enabling-studies for ORMD-0901 followed by an IND and Phase II multi-site study in the U.S.

## Income Statement—Oramed Pharmaceuticals Inc. (ORMP)

\$ in Millions

	2012A	2013A	2014A	2015A	1Q16A	2Q16A	3Q16A	4Q16E	2016E	2017E	2018E	2019E	2020E
Royalties													
ORMD 0801- T2D	-	-	-	-	-	-	-	-	-	-	-	-	5.3
ORMD 0801- T1D	-	-	-	-	-	-	-	-	-	-	-	-	-
ORMD-0901 -T2D	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total Product Royalties</b>	-	-	-	-	-	-	-	-	-	-	-	-	<b>5.3</b>
<b>Gross Profit</b>	-	-	-	-	-	<b>0.1</b>	<b>0.2</b>	-	<b>0.3</b>	-	-	-	<b>5.3</b>
Operating Expenses:													
Research and Development	(1.7)	(2.3)	(3.3)	(4.8)	(1.9)	(1.3)	(1.7)	(2.0)	(6.9)	(8.1)	(9.4)	(10.5)	(11.2)
Selling, General and Administrative	(1.2)	(2.0)	(2.6)	(2.6)	(0.5)	(0.7)	(0.6)	(1.1)	(2.9)	(3.4)	(3.9)	(4.5)	(4.9)
<b>Total Operating Expenses</b>	(2.9)	(4.3)	(5.9)	(7.4)	(2.4)	(2.0)	(2.3)	(3.1)	(9.8)	(11.4)	(13.3)	(15.0)	(16.1)
<i>Growth</i>	18%	49%	37%	25%	13%	-17%	12%	36%	33%	16%	16%	13%	7%
<i>% of Revenue</i>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	304%
<b>Operating Profit/(Loss) (EBIT)</b>	(2.9)	(4.3)	(5.9)	(7.4)	(2.4)	(2.0)	(2.3)	(3.1)	(9.8)	(11.4)	(13.3)	(15.0)	(10.8)
<i>Growth</i>	18%	49%	37%	25%	13%	-17%	12%	36%	33%	16%	16%	13%	-28%
Financial income	0.0	0.2	0.2	0.2	0.1	0.1	0.1	0.0	0.3	0.2	0.6	0.4	0.5
Financial expenses	(0.2)	(0.3)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-	(0.1)	(0.3)	(0.9)	(1.6)	(2.2)
Other Income (Expense), Net	(0.2)	-	-	-	-	-	-	-	-	-	-	-	-
<b>Net Profit/(Loss) - Pretax</b>	(3.3)	(4.4)	(5.7)	(7.2)	(2.4)	(1.9)	(2.2)	(3.1)	(9.6)	(11.6)	(13.6)	(16.2)	(12.5)
<i>Tax Rate</i>	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
(Taxes)/Tax Benefits	(0.1)	0.2	(0.0)	0.0	-	-	-	-	-	-	-	-	-
<b>Net Income (After Taxes)</b>	(3.3)	(4.2)	(5.7)	(7.2)	(2.4)	(1.9)	(2.2)	(3.1)	(9.6)	(11.6)	(13.6)	(16.2)	(12.5)
<i>Growth</i>	114%	27%	35%	27%	13%	-19%	11%	42%	32%	21%	17%	19%	-22%
<b>Basic Net Profit/ (Loss) per Common Share</b>	<b>(0.57)</b>	<b>(0.59)</b>	<b>(0.62)</b>	<b>(0.67)</b>	<b>(0.21)</b>	<b>(0.15)</b>	<b>(0.16)</b>	<b>(0.23)</b>	<b>(0.76)</b>	<b>(0.79)</b>	<b>(0.73)</b>	<b>(0.87)</b>	<b>(0.67)</b>
<i>Weighted Average Shares Outstanding</i>	5.9	7.2	9.2	10.8	11.6	12.7	13.1	13.1	12.6	14.6	18.6	18.6	18.6
<i>Growth</i>	-91%	23%	28%	17%	1%	9%	4%	0.0%	17%	16%	27%	0%	0%
<b>Diluted Net Profit/ (Loss) per Common Share</b>	<b>(0.57)</b>	<b>(0.59)</b>	<b>(0.62)</b>	<b>(0.67)</b>	<b>(0.21)</b>	<b>(0.15)</b>	<b>(0.16)</b>	<b>(0.23)</b>	<b>(0.76)</b>	<b>(0.79)</b>	<b>(0.73)</b>	<b>(0.87)</b>	<b>(0.67)</b>
<i>Fully Diluted Average Shares</i>	5.9	7.2	9.2	10.8	11.6	12.7	13.1	13.1	12.6	14.6	18.6	18.6	18.6
<i>Growth</i>	-91%	23%	28%	17%	1%	9%	4%	0.0%	17%	16%	27%	0%	0%

Christopher S. James, M.D. 646.885.5470 . cjames@fbr.com

Source: Company reports and FBR Research

## Balance Sheet—Oramed Pharmaceuticals Inc. (ORMP)

\$ in Millions

	2012A	2013A	2014A	2015A	1Q16A	2Q16A	3Q16A	4Q16E	2016E	2017E	2018E	2019E	2020E
<b>Current assets:</b>													
Cash and cash equivalents	4.4	2.3	1.8	3.2	1.9	3.2	3.3	11.3	11.3	41.1	82.1	90.8	100.7
Short-term deposits	0.5	5.2	18.5	11.9	11.1	20.3	18.0	8.9	8.9	6.7	5.0	5.2	5.4
Marketable securities	0.2	1.0	1.0	2.1	2.0	2.1	3.4	1.7	1.7	1.3	1.1	1.1	1.2
Restricted cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts receivable - other	0.1	-	-	-	-	-	-	-	-	-	-	-	0.4
Prepaid expenses and other current assets	0.0	0.1	0.1	0.1	0.1	0.4	0.4	0.1	0.1	0.1	0.1	0.1	0.1
Related parties	0.0	0.0	0.3	-	-	-	-	-	-	-	-	-	-
Grants receivable from the Office of the Chief Scientist	0.1	0.1	0.1	-	-	-	-	-	-	-	-	-	-
<b>Total current assets</b>	<b>5.3</b>	<b>8.6</b>	<b>21.8</b>	<b>17.4</b>	<b>15.2</b>	<b>26.0</b>	<b>25.1</b>	<b>22.0</b>	<b>22.0</b>	<b>49.3</b>	<b>88.4</b>	<b>97.2</b>	<b>107.9</b>
Investment in a joint venture	-	-	-	-	-	-	-	-	-	-	-	-	-
Long-term deposits and investment	0.0	0.0	0.0	8.0	8.1	10.6	10.6	10.6	10.6	10.6	10.6	10.6	10.6
Marketable securities	-	-	-	0.9	0.6	1.8	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Amounts funded for employee rights upon retirement	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Property and equipment, net	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.5	1.0	3.0
<b>Total assets</b>	<b>5.3</b>	<b>8.7</b>	<b>21.8</b>	<b>26.4</b>	<b>23.9</b>	<b>38.4</b>	<b>36.3</b>	<b>33.2</b>	<b>33.2</b>	<b>60.7</b>	<b>100.1</b>	<b>109.4</b>	<b>122.1</b>
<b>Liabilities and stockholders' equity</b>													
<b>Current liabilities:</b>													
Accounts payable and accrued expenses	0.6	0.5	0.9	1.0	0.8	0.8	0.6	0.6	0.6	0.6	0.6	1.1	1.3
Advance on account of license agreement	-	-	-	0.5	0.5	0.6	0.7	0.7	0.7	0.7	0.7	0.7	0.7
Related parties	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Account payable with former shareholder	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total current liabilities</b>	<b>0.6</b>	<b>0.5</b>	<b>1.0</b>	<b>1.5</b>	<b>1.3</b>	<b>1.5</b>	<b>1.3</b>	<b>1.3</b>	<b>1.3</b>	<b>1.3</b>	<b>1.3</b>	<b>1.8</b>	<b>2.0</b>
Warrants	0.6	-	-	-	-	-	-	-	-	-	-	-	-
Long-term debt	-	-	-	-	-	-	-	-	-	25.0	50.0	75.0	100.0
Employee rights upon retirement	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Provision for uncertain tax position	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	-	-	-	-	-	4.1	3.9	3.9	3.9	3.9	3.9	3.9	3.9
<b>Total liabilities</b>	<b>1.5</b>	<b>0.5</b>	<b>1.0</b>	<b>1.5</b>	<b>1.3</b>	<b>5.7</b>	<b>5.3</b>	<b>5.3</b>	<b>5.3</b>	<b>30.3</b>	<b>55.3</b>	<b>80.8</b>	<b>106.0</b>
Common stock	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Additional paid-in capital	21.6	29.9	48.0	59.2	59.7	71.6	71.8	71.8	71.8	85.8	113.8	113.8	113.8
Accumulated other comprehensive income	-	0.3	0.5	0.6	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Accumulated Loss	(17.9)	(22.1)	(27.8)	(35.1)	(37.4)	(39.3)	(41.3)	(44.3)	(44.3)	(55.9)	(69.5)	(85.6)	(98.2)
<b>Total stockholders' (deficit) equity</b>	<b>3.8</b>	<b>8.1</b>	<b>20.8</b>	<b>24.8</b>	<b>22.5</b>	<b>32.7</b>	<b>31.0</b>	<b>27.9</b>	<b>27.9</b>	<b>30.3</b>	<b>44.8</b>	<b>28.6</b>	<b>16.1</b>
<b>Total liabilities and stockholders' equity</b>	<b>5.3</b>	<b>8.7</b>	<b>21.8</b>	<b>26.4</b>	<b>23.9</b>	<b>38.4</b>	<b>36.3</b>	<b>33.2</b>	<b>33.2</b>	<b>60.7</b>	<b>100.1</b>	<b>109.4</b>	<b>122.1</b>

Christopher S. James, M.D. 646.885.5470 . cjames@fbr.com

Source: Company reports and FBR Research

## Discounted Cash Flow (DCF) Analysis—Oramed Pharmaceuticals Inc. (ORMP)

\$ in Millions

	2015A	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	TVE
<b>EBIT</b>	<b>(7.4)</b>	<b>(9.6)</b>	<b>(11.4)</b>	<b>(13.3)</b>	<b>(15.0)</b>	<b>(10.8)</b>	<b>2.2</b>	<b>54.5</b>	<b>119.8</b>	<b>213.6</b>	<b>322.0</b>	<b>376.4</b>	<b>420.5</b>	<b>470.8</b>	<b>528.1</b>	<b>593.6</b>	
Effective Tax Rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	30.0%	30.0%	30.0%	30.0%	30.0%	30.0%	30.0%	30.0%	
Tax Expense	-	-	-	-	-	-	-	-	(35.9)	(64.1)	(96.6)	(112.9)	(126.2)	(141.2)	(158.4)	(178.1)	
<b>NOPAT</b>	<b>(7.4)</b>	<b>(9.6)</b>	<b>(11.4)</b>	<b>(13.3)</b>	<b>(15.0)</b>	<b>(10.8)</b>	<b>2.2</b>	<b>54.5</b>	<b>83.9</b>	<b>149.5</b>	<b>225.4</b>	<b>263.5</b>	<b>294.4</b>	<b>329.6</b>	<b>369.7</b>	<b>415.5</b>	
Add: Depreciation & Amortization	0.0	0.0	0.0	0.0	0.1	0.1	0.4	1.5	1.9	2.7	4.2	6.5	8.8	11.3	13.8	16.4	
Less: Change in Working Capital	0.9	3.8	(0.0)	(0.0)	0.5	(0.2)	(0.9)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	
Less: Capital Expenditures	(0.0)	(0.1)	(0.2)	(0.3)	(0.5)	(2.1)	(7.8)	(3.6)	(7.3)	(12.9)	(19.2)	(22.4)	(25.0)	(28.0)	(31.4)	(35.3)	
<b>Unlevered Free Cash Flow</b>	<b>(6.5)</b>	<b>(5.8)</b>	<b>(11.6)</b>	<b>(13.6)</b>	<b>(15.0)</b>	<b>(13.0)</b>	<b>(6.0)</b>	<b>52.4</b>	<b>78.4</b>	<b>139.3</b>	<b>210.5</b>	<b>247.5</b>	<b>278.2</b>	<b>312.8</b>	<b>352.1</b>	<b>396.6</b>	
Terminal Value																	404.6
<b>Total Free Cash Flows</b>	<b>(6.5)</b>	<b>(5.8)</b>	<b>(11.6)</b>	<b>(13.6)</b>	<b>(15.0)</b>	<b>(13.0)</b>	<b>(6.0)</b>	<b>52.4</b>	<b>78.4</b>	<b>139.3</b>	<b>210.5</b>	<b>247.5</b>	<b>278.2</b>	<b>312.8</b>	<b>352.1</b>	<b>396.6</b>	<b>404.6</b>
Discount Period	0.9	0.2	1.2	2.2	3.2	4.2	5.2	6.2	7.2	8.2	9.2	10.2	11.2	12.2	13.2	14.2	14.2
Discount Factor	-	1.0	0.9	0.8	0.7	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2
<b>Discounted Free Cash Flows</b>	<b>-</b>	<b>(5.7)</b>	<b>(10.1)</b>	<b>(10.3)</b>	<b>(10.1)</b>	<b>(7.7)</b>	<b>(3.1)</b>	<b>24.1</b>	<b>31.7</b>	<b>49.7</b>	<b>66.2</b>	<b>68.6</b>	<b>67.9</b>	<b>67.3</b>	<b>66.8</b>	<b>66.3</b>	<b>67.6</b>

Christopher S. James, M.D. 646.885.5470 . cjames@fbr.com

Source: Company reports and FBR Research

# Sum-of-the-Parts (SOTP) Analysis—Oramed Pharmaceuticals Inc. (ORMP)

\$ in Millions

	2015A	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	TVE	
<b>ORMD-0801 - T2D</b>																		
Royalty Revenue					-	5	12	57	83	174	225	261	303	352	409	475		
Gross Income	-	-	-	-	-	5	12	57	83	174	225	261	303	352	409	475		
R&D Share	(4)	(6)	(7)	(8)	(9)	(9)	(10)	(9)	(13)	(28)	(36)	(42)	(49)	(56)	(65)	(76)		
G&A Share	(2)	(3)	(3)	(3)	(4)	(4)	(5)	(5)	(5)	(5)	(5)	(6)	(6)	(6)	(7)	(7)		
Operating Income	(6.6)	(8.9)	(10.2)	(11.7)	(13.1)	(8.4)	(1.8)	43.4	64.9	141.0	183.4	213.6	248.8	289.7	337.1	392.2		
Less: Tax	-	-	-	-	-	-	-	-	(19)	(42)	(55)	(64)	(75)	(87)	(101)	(118)		
NOPAT	(7)	(9)	(10)	(12)	(13)	(8)	(2)	43	45	99	128	150	174	203	236	275		
Plus: Share of Noncash	1	3	(0)	(0)	0	(2)	7	(2)	(3)	(7)	(9)	(9)	(10)	(10)	(11)	(12)		
Unlevered FCF	(6)	(5)	(10)	(12)	(13)	(10)	5	42	42	92	120	141	165	192	225	262	2,329	
Discount Factor	-	1.0	0.9	0.8	0.7	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2	
Discounted FCF	-	(5)	(9)	(9)	(9)	(6)	3	19	17	33	38	39	40	41	43	44	389	ORMD-0801 - T2D 670
<b>ORMD-0801 - T1D</b>																		
Royalty Revenue	-	-	-	-	-	-	3	5	22	29	54	63	65	68	71	74		
Gross Income	-	-	-	-	-	-	3	5	22	29	54	63	65	68	71	74		
R&D Share	(0)	(0)	(0)	(0)	(1)	(1)	(1)	(1)	(4)	(5)	(9)	(10)	(10)	(11)	(11)	(12)		
G&A Share	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)		
Operating Income	(0.4)	(0.5)	(0.6)	(0.7)	(0.8)	(1.0)	1.4	4.0	18.3	24.0	45.2	52.4	54.6	56.9	59.3	61.7		
Less: Tax	-	-	-	-	-	-	-	-	(5)	(7)	(14)	(16)	(16)	(17)	(18)	(19)		
NOPAT	(0)	(0)	(1)	(1)	(1)	(1)	1	4	13	17	32	37	38	40	41	43		
Plus: Share of Noncash	0	0	(0)	(0)	0	(0)	(5)	(0)	(1)	(1)	(2)	(2)	(2)	(2)	(2)	(2)		
Unlevered FCF	(0)	(0)	(1)	(1)	(1)	(1)	(4)	4	12	16	30	34	36	38	40	41	367	
Discount Period	0.9	0.2	1.2	2.2	3.2	4.2	5.2	6.2	7.2	8.2	9.2	10.2	11.2	12.2	13.2	14.2		
Discount Factor	-	1.0	0.9	0.8	0.7	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2	
Discounted FCF	-	(0)	(1)	(1)	(1)	(1)	(2)	2	5	6	9	10	9	8	7	7	61	ORMD-0801 - T1D 119
<b>ORMD-0901 GLP-1 - T2D</b>																		
Royalty Revenue						-	5	10	41	55	105	124	131	139	148	157		
Gross Income	-	-	-	-	-	-	5	10	41	55	105	124	131	139	148	157		
R&D Share	(0)	(0)	(0)	(1)	(1)	(1)	(2)	(2)	(4)	(5)	(10)	(12)	(13)	(14)	(15)	(16)		
G&A Share	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(1)	(1)	(1)	(1)	(1)	(1)	(2)	(2)		
Operating Income	(0.4)	(0.5)	(0.6)	(0.8)	(1.1)	(1.5)	2.6	7.2	36.6	48.6	93.5	110.3	117.1	124.2	131.8	139.7		
Less: Tax	-	-	-	-	-	-	-	-	(11)	(15)	(28)	(33)	(35)	(37)	(40)	(42)		
NOPAT	(0)	(0)	(1)	(1)	(1)	(1)	3	7	26	34	65	77	82	87	92	98		
Plus: Share of Noncash	0.0	0.2	(0.0)	(0.0)	0.0	(0.3)	(9.8)	(0.3)	(1.7)	(2.3)	(4.3)	(4.7)	(4.5)	(4.4)	(4.4)	(4.4)		
Unlevered FCF	(0)	(0)	(1)	(1)	(1)	(2)	(7)	7	24	32	61	73	77	83	88	93	830	
Discount Factor	-	1.0	0.9	0.8	0.7	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2	
Discounted FCF	-	(0)	(1)	(1)	(1)	(1)	(4)	3	10	11	19	20	19	18	17	16	139	ORMD-0901 GLP-1 - T2D 264

Christopher S. James, M.D. 646.885.5470 . cjames@fbr.com

Source: Company reports and FBR Research



\*Closing price of last trading day immediately prior to the date of this publication unless otherwise indicated.

## Important Information

FBR is the global brand for FBR & Co. and its subsidiaries.

This report has been prepared by FBR Capital Markets & Co. (FBRC), a subsidiary of FBR & Co.

FBRC is a broker-dealer registered with the SEC and member of FINRA, the NASDAQ Stock Market and the Securities Investor Protection Corporation (SIPC). The address for FBRC is 1300 North 17th Street Suite 1400, Arlington, VA 22209.

FBR Capital Markets LT, Inc. is an affiliate of FBRC and provides services for trading non-securities products.

All references to FBR & Co. mean FBR Capital Markets & Co. (FBRC) and its affiliates.

## Company-Specific Disclosures

Within the next three months, FBR, and/or FBR Affiliates, expects to receive or intends to seek compensation for investment banking services from this issuer: Oramed Pharmaceuticals Inc..

FBR, and/or FBR Affiliate(s), has managed or co-managed a public offering of the company's securities and has received compensation for investment banking services from the company as a client of FBR, and/or FBR Affiliates, during the past twelve months: Oramed Pharmaceuticals Inc..

FBR, and/or FBR Affiliate(s), has been engaged by the issuer to provide investment banking services. The issuer is a client of FBR, and/or FBR Affiliates, and receives investment banking services: Oramed Pharmaceuticals Inc..

For up-to-date company disclosures including price charts, please click on the following link or paste URL in a web browser:

[www.fbr.com/disclosures](http://www.fbr.com/disclosures)

## General Disclosures

### Information about the Research Analyst Responsible for this report:

The primary analyst(s) covering the issuer(s), Christopher S. James, M.D., certifies (certify) that the views expressed herein accurately reflect the analyst's personal views as to the subject securities and issuers and further certifies that no part of such analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the analyst in the report. The analyst(s) responsible for this research report has received and is eligible to receive compensation, including bonus compensation, based on FBR's overall operating revenues, including revenues generated by its investment banking activities.

### Information about FBR's Conflicts Management Policy:

Our Research conflicts management policy is available at: <http://www.fbr.com/conflicts-management-policy>.

### Information about investment banking:

In the normal course of its business, FBR seeks to perform investment banking and other services for various companies and to receive compensation in connection with such services. As such, investors should assume that FBR intends to seek investment banking or other business relationships with the companies.

### Information about our recommendations, holdings and investment decisions:

The information and rating included in this report represent the long-term view as described more fully below. The analyst may have different views regarding short-term trading strategies with respect to the stocks covered by the rating, options on such stocks, and/or other securities or financial instruments issued by the company, and such views may be made available to all or some of our clients from time to time. Our brokers also may make recommendations to their clients, and our affiliates may make investment decisions that are contrary to the recommendations contained in this research report. Such recommendations or investment decisions may be based on the particular investment strategies, risk tolerances, and other investment factors of that particular client or affiliate. From time to time, FBR, its affiliated entities, and their respective directors, officers, employees, or members of their immediate families may have a long or short position in the securities or other financial instruments mentioned in this report.

We provide to certain customers on request specialized research products or services that focus on covered stocks from a particular perspective. These products or services include, but are not limited to, compilations, reviews, and analysis that may use different research methodologies or focus on the prospects for individual stocks as compared to other covered stocks or over differing time horizons or under assumed market events or conditions. Readers should be aware that we may issue

investment research on the subject companies from a technical perspective and/or include in this report discussions about options on stocks covered in this report and/or other securities or financial instruments issued by the company. These analyses are different from fundamental analysis, and the conclusions reached may differ. Technical research and the discussions concerning options and other securities and financial instruments issued by the company do not represent a rating or coverage of any discussed issuer(s). The disclosures concerning distribution of ratings and price charts refer to fundamental research and do not include reference to technical recommendations or discussions concerning options and other securities and financial instruments issued by the company.

Our analysts' short-term views, recommendations by our brokers, views contained in products and services provided to customers on an individualized basis, and/or strategies, analysis or decisions made by FBR & Co. or its affiliates and their respective directors, officers, employees, or members of their immediate families may reach different conclusions than those published by the analyst in this report and could impact the price of the securities mentioned in this report.

### **Important Information Concerning Options Transactions:**

This discussion is directed to experienced professional investors with a high degree of sophistication and risk tolerance.

Options transactions are not suitable for all investors. This brief statement does not address all of the risks or other significant aspects of entering into any particular transaction. Tax implications are an important consideration for options transactions. Prior to undertaking any trade you should discuss with your preferred tax, ERISA, legal, accounting, regulatory, or other advisor how such particular trade may affect you.

Opinion with respect to options is distinct from fundamental research analysis. Opinion is current as of the time of publication, and there should be no expectation that it will be updated, supplemented, or reviewed as information changes. We make no commitment to continue to follow any ideas or information contained in this section. Analysis does not consider the cost of commissions. Supporting documentation is available upon request.

**Please ensure that you have read and understood the current options risk disclosure document before entering into any options transactions. The options risk disclosure document can be accessed at the following Web address: <http://optionsclearing.com/about/publications/character-risks.jsp>. If this link is inaccessible, please contact your representative.**

### Risks

Some options strategies may be complex, high risk, and speculative. There are potentially unlimited combinations of hedged and unhedged options strategies that expose investors to varying degrees of risk. Generally, buyers establishing long options positions risk the loss of the entire premium paid for the position, while sellers establishing short options positions have unlimited risk of loss. There are a number of commonly recognized options strategies, that expose investors to varying degrees of risk, some of which are summarized below:

Buying Calls or Puts--Investors may lose the entire premium paid.

Selling Covered Calls--Selling calls on long stock position. Risk is that the stock will be called away at strike, limiting investor profit to strike plus premium received.

Selling Uncovered Calls--Unlimited risk that investors may experience losses much greater than premium received.

Selling Uncovered Puts--Significant risk that investors will experience losses much greater than premium income received.

Buying Vertical Spreads (Calls--long call and short call with higher strike; Puts--long put and short put with lower strike) Same expiration month for both options. Investors may lose the entire premium paid.

Buying Calendar Spreads (different expiration months with short expiration earlier than long). Investors may lose the entire premium paid.

Selling Call or Put Vertical Spreads (Calls--short call and long call with higher strike; Puts--short put and long put with a lower strike, same expiration month for both options.) Investors risk the loss of the difference between the strike prices, reduced by the premium received.

Buying Straddle--Buying a put and a call with the same underlying strike and expiration. Investors risk loss of the entire premium paid.

Selling Straddle--Sale of call and put with the same underlying strike and expiration.) Unlimited risk that investors will experience losses much greater than the premium income received.

Buying Strangle--Long call and long put, both out of the money, with the same expiration and underlying security. Investors may lose the entire premium paid.

Selling Strangle--Short call and put, both out of the money, with the same expiration and underlying security. Unlimited risk of loss in excess premium collected.

**Important Information about Convertible & Other Fixed-Income Securities and Financial Instruments:**

This discussion is directed to experienced professional investors with a high degree of sophistication and risk tolerance.

Opinion with respect to convertible, other fixed-income securities and other financial instruments is distinct from fundamental research analysis. Opinion is current as of the time of publication, and there should be no expectation that it will be updated, supplemented, or reviewed as information changes. We make no commitment to continue to follow any ideas or information contained in this section.

Research analysts may consult Credit Sales and Trading personnel when preparing commentary on convertible and fixed-income securities and other financial instruments. FBR may be a market maker in the company's convertible or fixed-income securities. FBR Capital Markets LT, Inc. may be a market maker in financial instruments that are not securities.

Securities and financial instruments discussed may be unrated or rated below investment grade, may be considered speculative, and should only be considered by accounts qualified to invest in such securities.

Securities and financial instruments discussed may not be registered or exempt from registration in all jurisdictions. Nonregistered securities discussed may be subject to a variety of unique risk considerations, including those related to liquidity, price volatility, and lack of widely distributed information.

Rule 144A securities are sold only to persons who are Qualified Institutional Buyers within the meaning of Rule 144A, under the Securities Act of 1933, as amended.

**Information about our rating system:**

FBR instituted the following three-tiered rating system on October 11, 2002, for securities it covers:

- Outperform (OP) — FBR expects that the subject company will outperform its peers over the next 12 months. We recommend that investors buy the securities at the current valuation.
- Market Perform (MP) — FBR expects that the subject company's stock price will be in a trading range neither outperforming nor underperforming its peers over the next 12 months.
- Underperform (UP) — FBR expects that the subject company will underperform its peers over the next 12 months. We recommend that investors reduce their positions until the valuation or fundamentals become more compelling.

A description of the five-tiered rating system used prior to October 11, 2002, can be found at <http://www.fbr.com/disclosures-pre-10702>.

Rating	FBR Research Distribution <sup>1</sup>	FBR Banking Services in the past 12 months <sup>1</sup>
BUY [Outperform]	65.54%	28.68%
HOLD [Market Perform]	32.29%	5.97%
SELL [Underperform]	2.17%	0.00%

(1) As of midnight on the business day immediately prior to the date of this publication.

**General Information about FBR Research:**

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable but is not guaranteed as to accuracy and does not purport to be complete. Opinion is as of the date of the report unless labeled otherwise and is subject to change without notice. Updates may be provided based on developments and events and as otherwise appropriate. Updates may be restricted based on regulatory requirements or other considerations. Consequently, there should be no assumption that updates will be made. FBR & Co. disclaims any warranty of any kind, whether express or implied, as to any matter whatsoever relating to this research report and any analysis, discussion or trade ideas contained herein. This research report is provided on an "as is" basis for use at your own risk, and FBR & Co. is not liable for any damages or injury resulting from use of this information. This report should not be construed as advice designed to meet the particular investment needs of any investor or as an offer or solicitation to buy or sell the securities or financial instruments mentioned herein, and any opinions expressed herein are subject to change. Some or all of the securities and financial instruments discussed in this report may be speculative, high risk, and unsuitable or inappropriate for many investors. FBR & Co. makes no representation as to the suitability or appropriateness of these securities or financial instruments for individual investors. Investors must make their own determination, either alone or in consultation with their own advisors, as to the suitability or appropriateness of such investments based upon factors

including their investment objectives, financial position, liquidity needs, tax status, and level of risk tolerance. These securities and financial instruments may be sold to or purchased from customers or others by FBR acting as principal or agent.

Securities and financial instruments issued by foreign companies and/or issued overseas may involve certain risks, including differences in accounting, reporting, and registration, as well as foreign currency, economic, and political risks.

This report and the securities and financial instruments discussed herein may not be eligible for distribution or sale in all jurisdictions and/or to all types of investors. This report is provided for information purposes only and does not represent an offer or solicitation in any jurisdiction where such offer would be prohibited.

Commentary regarding the future direction of financial markets is illustrative and is not intended to predict actual results, which may differ substantially from the opinions expressed herein. If any hyperlink is inaccessible, call 800.846.5050 and ask for Editorial.

FBR utilizes a tiered approach to service its clients. The services provided by FBR's research analysts to clients vary, based upon a variety of factors including, but not limited to, client preferences and the extent of a client's total relationship with the Firm. FBR does not provide any of the Firm's clients with access to unpublished research opinion. FBR provides clients across all tiers equal access to research reports.

#### Pairs Trade Disclaimer

From time to time FBR Research Analysts will offer short term trading ideas, including identifying a paired trade. In a paired trade an investor buys the securities of one company and sells the securities of another company. The idea to buy the securities of one company and sell the securities of the other company is based on the expected short term price move or relative value between the two companies mentioned in the paired trade, not between the companies and any other companies. In contrast, the recommendations in a Research Analyst's published report reflects the Research Analyst's views on a company over the long term (i.e., the next twelve (12) months) relative to other companies covered by the Research Analyst. The trade idea in a paired trade is unrelated to the Research Analyst's long term view of the companies as expressed in the Research Analyst's most recently published research report. A paired trade idea to sell a company that is rated as a market perform or higher, or to buy a security that is a market perform or lower, is not inconsistent because the call to sell or buy the company is relative to the other company mentioned in the paired trade over the short term; it is not a long term view relative to other companies covered by the Research Analyst.

#### **Important information for French addresses and potential investors:**

Addresses and potential investors based in France expressly acknowledge that they have not been subject to any kind of solicitation by FBR Capital Markets & Co, as defined under Article L.341-1 and seq. of the French Monetary and Financial code.

The above analyses have not been prepared in the context of a public offering of financial instruments in France within the meaning of Article L.411-1 and seq. of the French Monetary and Financial code and shall not be deemed to be drawn up for the purpose of providing investment services as defined under Article L.321-1 and seq. of the French Monetary and Financial code. In this respect, the above analyses shall not be qualified as a personalized investment advice related to financial instruments under French law and shall therefore not be deemed to be qualified as investment advice provided by FBR Capital Markets & Co.


Addresses and potential investors based in France may initiate the first contact with FBR Capital Markets & Co in order to get additional information on financial analyses and services provided by the latter. By doing so, addresses and potential investors based in France expressly acknowledge that the banking and financial solicitation regime as defined under Article L.341-1 and seq. of the French Monetary and Financial code shall not be applicable.

#### **Information for Clients of FBRC:**

This publication has been approved by FBR Capital Markets & Co. (FBRC), which accepts responsibility for its contents and its distribution to our clients. Any FBRC client who receives this research and wishes to effect a transaction in the securities or financial instruments discussed should contact and place orders with an FBRC Sales representative or a representative of FBR Capital Markets LT, Inc. for financial instruments that are not securities.

Copyright 2016 FBR & Co.

## Rating and Price Target History for: Oramed Pharmaceuticals Inc. (ORMP) as of 07-06-2016



Created by BlueMatrix